Bullous Pemphigoid (BP) is a serious cutaneous autoimmune disease with distinctly associated comorbidities such as neurological disorders, hypertension, and diabetes mellitus. Recently, the use of Dipeptidyl Peptidase-4 Inhibitors/gliptins (DPP4i) to control hyperglycemia was linked to the increasing prevalence of Type 2 Diabetes Mellitus (T2DM) among patients with newly diagnosed BP,1 demonstrating that the association of different drugs to certain comorbidities might partly account for the observed link of some comorbidities to BP. This evidence concerns the gene DPP4 and bullous pemphigoid.